- Raw materials
- Hormonal Agents
- Gonadotrophic
- Chorionic gonadotropin
Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Chorionic gonadotropin API Manufacturers & Suppliers
1 verified results
Commercial-scale Suppliers
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Chorionic Gonadotropin (Human) | CAS No: 9002-61-3 | GMP-certified suppliers
A medication that supports treatment of cryptorchidism and male hypogonadotropic hypogonadism while aiding ovulation induction in appropriately prepared anovulatory women for reproductive management needs.
Therapeutic categories
Primary indications
- For the treatment of prepubertal cryptorchidism (not due to anatomical obstruction), for the treatment of selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males and for the induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulation is secondary and not due to primary ovarian failure, and who has been appropriately pretreated with human menotropins
Product Snapshot
- Injectable peptide hormone supplied mainly as liquid and lyophilized powders for intramuscular or subcutaneous administration
- Used in male cryptorchidism and hypogonadotropic hypogonadism, and for ovulation induction in anovulatory infertility
- Approved for human use in the US and Canada, with additional veterinary approvals
Clinical Overview
Pharmacologically, the hormone binds and activates the LHCG receptor on ovarian theca and luteal cells and on testicular Leydig cells. This receptor activation promotes progesterone secretion by the corpus luteum in females and androgen production in males. The pharmacodynamic profile is closely aligned with pituitary LH, with minimal FSH-like activity.
As a large glycoprotein composed of alpha and beta subunits, chorionic gonadotropin follows the disposition profile typical of peptide hormones. It is administered parenterally due to negligible oral bioavailability. After injection, it distributes primarily within extracellular fluid and undergoes metabolic degradation by proteolytic pathways. Elimination occurs via renal and hepatic mechanisms, with an effective half-life generally reported in the range of one to two days depending on formulation and route.
Safety considerations include the risk of ovarian hyperstimulation when used for fertility treatment, fluid retention, and potential exacerbation of hormone-sensitive conditions. In males, gynecomastia can occur due to increased estrogen production. Use requires monitoring of endocrine response and avoidance in patients with hormone-dependent tumors or unrelated causes of testicular descent failure. Preparations are derived from the urine of pregnant individuals and are highly purified to minimize pyrogenicity and immunologic reactivity.
Commercially, the API is used in injectable products for reproductive endocrinology and in certain veterinary reproductive applications.
For API procurement, sourcing should prioritize validated purification processes, control of biological origin materials, and compliance with pharmacopeial specifications to ensure consistency, purity, and traceability of the hormone preparation.
Identification & chemistry
| Generic name | Chorionic Gonadotropin (Human) |
|---|---|
| Molecule type | Biotech |
| CAS | 9002-61-3 |
| UNII | 20ED16GHEB |
| DrugBank ID | DB09126 |
Pharmacology
| Summary | Human chorionic gonadotropin acts as an agonist at the lutropin‑choriogonadotropic hormone receptor, mimicking luteinizing hormone with minor follicle‑stimulating activity. Activation of this receptor promotes gonadal steroidogenesis, including androgen production in Leydig cells and progesterone synthesis in the corpus luteum. These endocrine effects support its use in conditions involving deficient LH-dependent reproductive function. |
|---|---|
| Pharmacodynamics | The action of HCG is virtually identical to that of pituitary LH, although HCG appears to have a small degree of FSH activity as well. It stimulates production of gonadal steroid hormones by stimulating the interstitial cells (Leydig cells) of the testis to produce androgens and the corpus luteum of the ovary to produce progesterone. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Lutropin-choriogonadotropic hormone receptor | Humans | ligand |
Formulation & handling
- Produced as a biotech peptide hormone requiring parenteral administration, typically supplied as lyophilized powder for IM or SC reconstitution.
- Formulations require protection from heat and agitation, with reconstituted solutions having limited stability and needing controlled cold-chain handling.
- Protein nature makes it susceptible to adsorption and degradation, so formulation commonly includes stabilizers and low‑interaction primary packaging.
Regulatory status
| Lifecycle | The API’s U.S. patent expired in 2021, indicating that the product is in a mature stage of its lifecycle with potential for generic competition. With availability in both the United States and Canada, the market is established and largely driven by post‑patent dynamics. |
|---|
| Markets | Canada, US |
|---|
Supply Chain
| Supply chain summary | Chorionic Gonadotropin (Human) is supplied primarily by a small group of originator manufacturers, with branded injectable products established in the US and Canada. Market presence is concentrated in these regions, with limited evidence of broader global distribution. The listed US patent expired in 2021, indicating that generic or follow‑on competition is likely already present or emerging. |
|---|
Chorionic gonadotropin is a type of Gonadotrophic
Gonadotrophic is a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that plays a crucial role in reproductive health. It includes a group of naturally occurring hormones known as gonadotropins, which are produced by the pituitary gland. These hormones, namely follicle-stimulating hormone (FSH) and luteinizing hormone (LH), regulate the reproductive processes in both males and females.
Gonadotrophic APIs are commonly used in various medical applications, particularly in the field of assisted reproductive technology (ART) and fertility treatments. They stimulate the development of ovarian follicles in females, promoting ovulation and enhancing the chances of successful conception. In males, these APIs stimulate the production of sperm cells and support the production of testosterone.
The pharmaceutical industry produces gonadotrophic APIs through advanced biotechnology techniques, such as recombinant DNA technology. This process involves the use of genetically engineered cells, typically from Chinese hamster ovary (CHO) cells, to produce highly pure and bioactive forms of FSH and LH.
Gonadotrophic APIs are typically formulated into injectable preparations, ensuring their efficient delivery and absorption into the bloodstream. These formulations are administered under the guidance of healthcare professionals and require precise dosing to achieve optimal therapeutic outcomes.
Overall, gonadotrophic APIs have revolutionized the field of reproductive medicine, providing effective solutions for infertility and hormonal imbalances. Their usage has helped countless individuals and couples to overcome fertility challenges and realize their dreams of starting a family.
Chorionic gonadotropin (Gonadotrophic), classified under Hormonal Agents
Hormonal agents are a prominent category of pharmaceutical active pharmaceutical ingredients (APIs) widely used in the medical field. These substances play a crucial role in regulating and modulating hormonal functions within the body. Hormonal agents are designed to mimic or manipulate the effects of naturally occurring hormones, allowing healthcare professionals to treat various endocrine disorders and hormonal imbalances.
Hormonal agents are commonly employed in the treatment of conditions such as hypothyroidism, hyperthyroidism, diabetes, and hormonal cancers. These APIs work by interacting with specific hormone receptors, either by stimulating or inhibiting their activity, to restore the balance of hormones in the body. They can be administered orally, intravenously, or through other routes depending on the specific medication and patient needs.
Pharmaceutical companies employ rigorous manufacturing processes and quality control measures to ensure the purity, potency, and safety of hormonal agent APIs. These APIs are synthesized using chemical or biotechnological methods, often starting from natural hormone sources or through recombinant DNA technology. Stringent regulatory guidelines are in place to guarantee the efficacy and safety of hormonal agent APIs, ensuring that patients receive high-quality medications.
As the demand for hormone-related therapies continues to grow, ongoing research and development efforts focus on enhancing the effectiveness and reducing the side effects of hormonal agent APIs. This includes the exploration of novel delivery systems, advanced formulations, and targeted drug delivery methods. By continuously advancing our understanding and capabilities in hormonal agents, the medical community can improve patient outcomes and quality of life for individuals with hormonal disorders.
Chorionic gonadotropin API manufacturers & distributors
Compare qualified Chorionic gonadotropin API suppliers worldwide. We currently have 1 companies offering Chorionic gonadotropin API, with manufacturing taking place in 1 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| Shanghai Tianwei Biology ... | Producer | China | China | CoA, JDMF | 6 products |
When sending a request, specify which Chorionic gonadotropin API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Chorionic gonadotropin API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
Frequently asked questions about Chorionic gonadotropin API
Sourcing
What matters most when sourcing GMP-grade Chorionic gonadotropin (Human)?
Which documents are typically required when sourcing Chorionic gonadotropin (Human) API?
Which manufacturers are known to produce Chorionic gonadotropin (Human) API?
How can I request quotes for Chorionic gonadotropin (Human) API from GMP suppliers?
Is a GMP audit report available for Chorionic gonadotropin (Human) manufacturers?
How many suppliers offer Chorionic gonadotropin (Human) API on Pharmaoffer?
Which countries are known to manufacture Chorionic gonadotropin (Human) API?
Which certifications do suppliers of Chorionic gonadotropin (Human) usually hold?
Technical
What is Chorionic gonadotropin (Human) (CAS 9002-61-3) used for?
Which therapeutic class does Chorionic gonadotropin (Human) fall into?
What conditions is Chorionic gonadotropin (Human) mainly prescribed for?
How does Chorionic gonadotropin (Human) work?
What should someone know about the safety or toxicity profile of Chorionic gonadotropin (Human)?
What are important formulation and handling considerations for Chorionic gonadotropin (Human) as an API?
Is Chorionic gonadotropin (Human) a biotech?
Are there special stability concerns for oral Chorionic gonadotropin (Human)?
Regulatory
Where is Chorionic gonadotropin (Human) approved or in use globally?
Pharmaoffer
How does Pharmaoffer’s Smart Sourcing Service help with Chorionic gonadotropin (Human) procurement?
Is Chorionic gonadotropin (Human) included in the PRO Data Insights coverage?
Where can I access the API market report for Chorionic gonadotropin (Human)?
